What it's for (Indications)
- Omalizumab is a highly specialized biologic medication indicated for the treatment of various allergic and inflammatory conditions.
- Its primary indications include the management of moderate to severe persistent allergic asthma in adults and adolescents (12 years of age and older) who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
- Additionally, it is approved for chronic spontaneous urticaria (CSU) in adults and adolescents (12 years of age and older) who remain symptomatic despite H1-antihistamine treatment.
- More recently, omalizumab has received approval for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease is inadequately controlled by nasal corticosteroids.
- Furthermore, it has expanded its utility with an indication for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosing regimen for omalizumab is highly individualized and depends significantly on the specific indication, patient weight, and baseline serum total immunoglobulin E (IgE) levels. For allergic asthma and chronic spontaneous urticaria, dosing is determined by a weight-based dose chart and baseline IgE levels, typically ranging from 75 mg to 375 mg administered subcutaneously every two or four weeks. For chronic rhinosinusitis with nasal polyps, the recommended dosage is typically 75 mg or 150 mg subcutaneously every two or four weeks, irrespective of IgE levels. For food allergy, the dosage is also based on weight and IgE levels, administered subcutaneously every two or four weeks, with a maximum single dose of 375 mg. Administration should always be performed under the supervision of a healthcare professional experienced in the diagnosis and treatment of severe allergic conditions, due to the risk of anaphylaxis. Careful adherence to the prescribing information is crucial for optimal therapeutic outcomes and patient safety. |
Safety & Warnings
Common Side Effects
- Omalizumab, while effective, is associated with a spectrum of potential side effects, ranging from common and generally mild to rare but severe adverse events.
- Common side effects often include local injection site reactions such as pain, swelling, itching, or redness at the site of administration.
- Other frequently reported adverse events include headache, nasopharyngitis, upper respiratory tract infection, sinusitis, arthralgia, and nausea.
- More serious and potentially life-threatening adverse reactions, though less common, can occur.
- These include anaphylaxis, which can manifest as bronchospasm, hypotension, syncope, angioedema, and urticaria, and may occur immediately or several hours after administration, even after prolonged treatment.
- There have also been reports of an increased incidence of malignancies in clinical trials, as well as cardiovascular and cerebrovascular adverse events.
- Parasitic infections and rare cases of Churg-Strauss-like syndrome have also been observed.
- Patients should be thoroughly counseled on these potential risks and monitored appropriately.
Serious Warnings
- Black Box Warning: **WARNING: RISK OF ANAPHYLAXIS.** Anaphylaxis, a life-threatening systemic hypersensitivity reaction, has been reported with omalizumab. This reaction can manifest as bronchospasm, hypotension, syncope, urticaria, angioedema of the throat or tongue, or other severe systemic symptoms. Anaphylaxis associated with omalizumab administration can occur rapidly, often within minutes of administration, but also has a delayed onset, occurring hours or even more than 24 hours after a dose. Furthermore, anaphylaxis has been reported after any dose, including the initial dose and doses administered after more than one year of regular treatment. Due to this significant risk, omalizumab should be administered in a healthcare setting under the supervision of a healthcare professional equipped to identify and treat anaphylaxis. Patients should be observed for an appropriate period after administration, and epinephrine and other appropriate medical treatments must be readily available for immediate use. Patients and caregivers must be thoroughly educated on the signs and symptoms of anaphylaxis and advised to seek immediate medical care if these symptoms develop.
- A critical warning associated with omalizumab therapy is the potential for anaphylaxis, which can be severe and life-threatening, occurring even after the first dose or after extended periods of treatment.
- Patients must be monitored for an appropriate period following administration, and healthcare facilities must be equipped with resources for immediate management of anaphylaxis, including epinephrine.
- Patients should be educated on recognizing the signs and symptoms of anaphylaxis and instructed to seek urgent medical attention if they occur.
- Additionally, there have been observations of a numerical imbalance in malignancies reported in omalizumab-treated patients compared to control groups in clinical trials, warranting careful consideration.
- Cases of severe systemic hypersensitivity reactions, including serum sickness-like reactions, have also been reported.
- The potential for an increased risk of cardiovascular and cerebrovascular events has been identified in some studies, although a causal link has not been definitively established.
- Patients with known parasitic infections should be treated prior to initiating omalizumab.
How it Works (Mechanism of Action)
Omalizumab functions as a recombinant DNA-derived humanized monoclonal antibody (IgG1 kappa) that specifically targets and binds to free immunoglobulin E (IgE) in the circulation and interstitial fluid. By binding to the Cε3 domain of IgE, omalizumab prevents IgE from attaching to its high-affinity receptor (FcεRI) on the surface of mast cells, basophils, and other inflammatory cells. This blockade effectively reduces the amount of free IgE available to trigger the allergic cascade. Consequently, it leads to a downregulation of FcεRI expression on effector cells, particularly basophils, thereby reducing the release of inflammatory mediators such as histamine and leukotrienes. This mechanism ultimately helps to mitigate the allergic and inflammatory responses characteristic of conditions like allergic asthma, chronic urticaria, and other IgE-mediated diseases, providing symptomatic relief and disease control.
Commercial Brands (Alternatives)
No other brands found for this formula.